Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

LabWare 7 to 8 Migration: Hidden CSV Pitfalls That Delayed Validation

A pharmaceutical organization planned to upgrade its Laboratory Information Management System (LIMS) from LabWare 7 to LabWare 8. Initially, the migration was considered a routine technical upgrade because both versions belonged to the same software family. However, during project execution, the CSV and Quality Assurance teams identified several validation challenges related to system architecture, documentation, data migration, interfaces, and security. As a result, the migration required a broader risk-based validation approach to maintain GMP compliance and inspection readiness. This case study highlights the key CSV pitfalls encountered during the migration and the practical actions required to reduce regulatory risk. In this case study, our team demonstrates how we supported the client throughout the LabWare 7 to 8 migration by identifying critical CSV risks, implementing a risk-based validation approach, and helping achieve GMP compliance and inspection readiness.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Change Classification: The upgrade was initially treated as a like-for-like change. However, LabWare 8 introduced new architecture, workflows, interfaces, and security features, making the validation scope much larger than expected.
  • Incomplete Requirements Mapping: The existing URS was reused with minimal updates, leaving several new LabWare 8 functions, including EM, dashboards, stability features, and security concepts, outside the documented validation scope.
  • Data Migration Risks: Changes to data structures, master data, and controlled vocabularies increased the risk of data integrity issues and required additional verification of historical records and business rules.
  • Interface Validation Complexity: The migration affected integrations with SAP, MES, laboratory instruments, and Environmental Monitoring systems, requiring more comprehensive interface and end-to-end validation.
  • User Roles, Security, and Audit Trail: New security capabilities and role management required a complete review of user permissions, segregation of duties, electronic signatures, and audit trail functionality.

Zamann Pharma Support’s Approach

  • Risk Assessment and Change Classification: The migration scope was reassessed with QA, QC, IT, and business teams to identify system changes and define an appropriate validation strategy.
  • Requirements Review: Existing validation documents were updated to include new LabWare 8 functionality while maintaining traceability between requirements, risk assessments, and test cases.
  • Data Migration Strategy: Migration rules, data reconciliation, acceptance criteria, and validation activities were defined for samples, specifications, stability data, Environmental Monitoring limits, and master data.
  • Interface Validation: Integrated systems were revalidated using both standard and error scenarios to verify complete and accurate data transfer.
  • Security and Audit Trail Assessment: User roles, access rights, electronic signatures, and audit trails were reviewed to confirm GMP compliance and support routine audit trail reviews.
  • QA Involvement: Quality Assurance participated throughout the project by reviewing and approving the migration strategy, validation approach, interface qualification, and security model.

Results Achieved

  • Improved Change Classification: The project correctly classified the migration as a major computerized system change, allowing the validation strategy to reflect the actual system impact.
  • Better Requirements Traceability: Updated validation documentation improved alignment between business requirements, risk assessments, and validation testing.
  • Reduced Data Migration Risk: A structured migration strategy strengthened verification of migrated data, master data, and historical records while supporting data integrity.
  • Stronger Interface Validation: Expanded interface testing improved confidence in traceability, error handling, and end-to-end data transfer.
  • Enhanced Compliance Readiness: Reviewing security controls, user roles, and audit trails improved GMP compliance and inspection readiness.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Can we reuse LabWare 7 validation documents during a LabWare 8 migration?

Not entirely. Although some legacy documentation may remain relevant, a LabWare 7 to 8 migration typically introduces changes to system architecture, workflows, interfaces, security, and functionality. Therefore, risk assessments, URS, test scripts, and traceability should be reviewed and updated before revalidation.

2. What is the biggest CSV risk when migrating laboratory data to LabWare 8?

The greatest risk is assuming that successful data transfer alone proves migration quality. Validation should also verify data integrity, business rules, master data consistency, specification history, and traceability to demonstrate that migrated records remain complete, accurate, and GMP compliant.

3. Why do inspectors focus on interface validation after a LIMS upgrade?

Interfaces connecting LIMS with ERP, MES, laboratory instruments, and Environmental Monitoring systems directly affect data integrity. Inspectors expect documented evidence that data transfers, error handling, audit trails, and end-to-end workflows have been validated under both normal and exception conditions.